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Abstract
Background:  The majority of our bones develop through the process of endochondral
ossification that involves chondrocyte proliferation and hypertrophic differentiation in the cartilage
growth plate. A large number of growth factors and hormones have been implicated in the
regulation of growth plate biology, however, less is known about the intracellular signaling
pathways involved. PI3K/Akt has been identified as a major regulator of cellular proliferation,
differentiation and death in multiple cell types.
Results and Discussion: Employing an organ culture system of embryonic mouse tibiae and
LY294002, a pharmacological inhibitor of PI3K, we show that inhibition of the pathway results in
significant growth reduction, demonstrating that PI3K is required for normal endochondral bone
growth in vitro. PI3K inhibition reduces the length of the proliferating and particularly of the
hypertrophic zone. Studies with organ cultures and primary chondrocytes in micromass culture
show delayed hypertrophic differentiation of chondrocytes and increased apoptosis in the presence
of LY294002. Surprisingly, PI3K inhibition had no strong effect on IGF1-induced bone growth, but
partially blocked the anabolic effects of C-type natriuretic peptide.
Conclusion:  Our data demonstrate an essential role of PI3K signaling in chondrocyte
differentiation and as a consequence of this, in the endochondral bone growth process.
Background
Bone formation occurs through two different mecha-
nisms: endochondral and intramembranous ossification.
Longitudinal growth of the axial and appendicular skele-
ton is a result of endochondral ossification (EO) that is
controlled by the cartilage growth plate [1]. EO involves
the aggregation of mesenchymal cells to form cartilagi-
nous nodules [2]. A subset of the cells in these nodules
matures further into growth plate chondrocytes.
During endochondral bone development in the limb,
growth plate chondrocytes undergo well-ordered and con-
trolled phases of cell proliferation, maturation, and apop-
tosis [3]. The growth plate can be divided into three main
chondrocyte subpopulations: the resting, proliferating
and hypertrophic chondrocytes. These populations are
arranged in distinct zones that are distinguishable by mor-
phological criteria, but are also characterized by specific
molecular markers. The proliferation and/or differentia-
tion of these subpopulations are controlled by a complex
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network of regulatory molecules [4]. Proliferative
chondrocytes synthesize type II collagen and form charac-
teristic columns; they then exit the cell cycle and become
post-mitotic prehypertrophic chondrocytes that differen-
tiate further into hypertrophic cells. Hypertrophic
chondrocytes express type X collagen and mineralize the
surrounding matrix. This differentiation process is fol-
lowed by apoptosis of hypertrophic chondrocytes, but
prior to their death, they deposit vascular endothelial
growth factor (VEGF) into their extracellular matrix,
which promotes the invasion of blood vessels into the car-
tilage tissue. Blood vessel invasion enables the recruit-
ment of osteoblasts and osteoclasts and replacement of
the cartilage scaffold by a calcified bone matrix [2-5]. This
final step results in the formation of trabecular bone (the
primary spongiosa). With continuing resorption of the
primary spongiosa by osteoclasts, the primary center splits
into two opposing growth plates, in each of which the
maturation of cartilage and subsequent remodeling into
bone continue, as long as new chondrocytes are generated
in the growth plates [6].
Hypertrophic chondrocytes play a pivotal role in coordi-
nating chondrogenesis and osteogenesis, as they provide
a scaffold for subsequent formation of trabecular bone
and secrete factors such as VEGF that control the activity
of other cells involved in EO. Therefore, the proper regu-
lation of chondrocyte differentiation and the coordina-
tion of chondrocyte progression through the cell cycle
have to be tightly regulated for normal bone growth. The
induction of growth arrest is a central feature of this phe-
notypic transition. For example, mice lacking the cyclin
dependent-kinase inhibitor p57/Kip2 exhibit several
developmental abnormalities including abnormal skele-
togenesis [7]. Moreover, numerous skeletal diseases are
caused by deregulation of cellular proliferation and
hypertrophic chondrocyte differentiation, such as a large
number of skeletal dysplasias that are characterized by
dwarfism, skeletal deformities, and frequently by early-
onset osteoarthritis [8].
Both local paracrine regulators and systemic hormones
control endochondral bone formation and bone remode-
ling throughout life. Insulin-like growth factor-I (IGF1)
and C-type natriuretic peptide (CNP) are among the
major stimulators of endochondral bone growth. IGF1 is
the most prominent growth factor involved in linear
growth regulation and it was shown to be essential for
growth plate chondrocyte development. The most promi-
nent effect of IGF1 is induction of chondrocyte hypertro-
phy, as shown both in IGF1 null mice and in bone
cultures treated with IGF1 [9-12]. In addition, studies
from our lab and others identified the CNP pathway as an
important anabolic regulator of endochondral bone
growth [13-15]. However, the molecular and cellular
mechanisms mediating the anabolic effects of both lig-
ands are not completely understood. Substantial progress
has been made in the past few years in understanding how
local signaling molecules, working through key transcrip-
tion factors such as Sox and Runx proteins, interact and
control the growth and differentiation of bones [3,5,16-
18]. However, the intracellular signaling pathways con-
necting extracellular signaling molecules to transcrip-
tional regulators are poorly understood.
Here we focus on Phosphatidylinositol 3-kinases (PI3Ks)
which represent a family of lipid kinases whose inositol
lipid products are key mediators of intracellular signaling
in many cell types [19]. PI3Ks are represented by a family
of eight distinct enzymes that can be divided into three
classes based on their structure and function [20]. Class I
PI3Ks have been the major focus of PI3K studies because
these isoforms are generally coupled to extracellular stim-
uli. The generation of D3-phosphorylated phosphoi-
nositides at the membrane by PI3Ks results in the
recruitment of certain signaling proteins to the plasma
membrane via their pleckstrin homology (PH) domains.
As such, PI3Ks are upstream regulators in a number of sig-
naling cascades that control proliferation, growth, cell
death, migration, metabolism, and a host of other biolog-
ical responses [20]. In addition, the PI3K pathway is
known as the major signaling cascade downstream IGF1
in many cell types [21-24].
Class I PI3Ks are reversibly inhibited by the pharmacolog-
ical compound LY294002, and more specifically class I
alpha isoforms by PI3-K α inhibitor IV from Calbiochem.
Genetic screens in model organisms have identified Akt
(protein kinase B) as the primary downstream mediator of
the effects of PI3K [25]. PtdIns (4, 5)P2 and PtdIns (3, 4,
5)P3 bind to the PH domain of Akt, recruiting the kinase
to the plasma membrane where Akt is phosphorylated
and activated [26-28]. Akt has been shown to be a critical
mediator of cell proliferation and survival [29]. In mice,
disruption of the most ubiquitously expressed member of
the Akt family of genes, Akt1, results in body size reduc-
tion compared to the wild-type littermates [30,31].
Therefore, the PI3K/Akt pathway is involved in prolifera-
tion, differentiation, cellular survival or a combination of
these processes in multiple cell types, from neurons to
fibroblasts [32] but its role in cartilage and bone develop-
ment has not been studied intensively and is the focus of
our study.
Results
LY294002 suppresses chondrocyte differentiation
Micromass cultures were incubated in medium for three
days to allow chondrogenic differentiation before addi-
tion of the PI3K inhibitor LY294002 (10 μM) or DMSOBMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
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(Dimethyl Sulfoxide, control) for up to 9 more days (e.g.
until 12 days of culture). PI3K inhibition caused a delay
in chondrocyte differentiation, as shown by decreased
accumulation of sulfated glycosaminoglycans (Alcian
blue stain), decreased mineralization (Alizarin red S) and
less staining for alkaline phosphatase activity compared to
cells treated with DMSO (Figure 1A). Alcian blue stain was
extracted and quantified spectrophotometrically, con-
firming a significant decrease in LY294002 treated micro-
mass cultures at day 9 (Figure 1B). Measurement of
Hoechst 33342 fluorescence demonstrated that
LY294002 treatment did not result in significant changes
in DNA content of cultures (Figure 1C). RNA was isolated
from the micromass cultures at days 6 and 9 of culture.
Real-time PCR experiments showed decreased relative lev-
els of collagen II (Figure 1D) and X (Figure 1E) transcripts
upon PI3K inhibition. These data demonstrate that PI3K
activity is required for normal progression of chondrocyte
differentiation.
PI3K inhibition results in reduced bone growth
We next investigated the role of PI3K/Akt signaling in the
three-dimensional context of an intact bone. Tibiae were
isolated from E 15.5 mice, measured and then incubated
with LY294002 (10 μM), PI3-K α inhibitor IV (500 nM)
or DMSO for six days. Immunohistochemistry demon-
strated that in control cultures, phosphorylated Akt (P-
Akt) proteins (indicating activity of the pathway) can be
found mostly in the late proliferative, prehypertrophic
and early hypertrophic areas (Figure 2A). P-Akt levels were
greatly reduced upon PI3K inhibition, demonstrating the
efficiency of the inhibitor. The difference between tibia
length in the beginning and at the end of the time course
represents bone growth. The bones treated with
LY294002 and PI3-K α inhibitor IV showed an average of
45% and 35% reduction in growth compared to tibiae
treated with DMSO (Figure 2B). Measurements of both
growth plates and the mineralized area showed that the
length of the two tibial growth plates (proximal and dis-
tal) was reduced in the LY294002 treated bones, whereas
the absolute length of the mineralized zone was not
affected (Figure 2C and Figure 2D). PI3-K α inhibitor IV
showed similar effects to LY294002 as observed in the
Alcian blue/Alizarin red stain (Figure 2C).
When the three parts of the bone (gp1-proximal growth
plate, gp2-distal growth plate, and min-mineralized area)
were calculated as a percentage of the entire length of the
bone, we noticed a relative increase in the length of the
mineralized zone upon PI3K inhibition (Figure 2E).
Treatment of tibiae with LY294002 results in smaller 
proliferative and hypertrophic zones
Histological sections of tibiae from E15.5 mice, cultured
for 6 days in the presence of LY294002 (10 μM) or DMSO,
were stained with H&E or Safranin O/Fast green. Growth
plate organization and columnar arrangement of cells
were not notably different after PI3K inhibition, but we
noticed a much smaller hypertrophic zone in LY294002
treated bones compared to the controls (Figure 3A). Sec-
tions were further analyzed using Openlab 4.0.4 software
to measure the length of different areas of the growth
plate. The hypertrophic (HZ) and proliferative (PZ) zones
of the growth plate of LY294002 treated tibiae were signif-
icantly shorter than in control. The resting zone (RZ) was
increased in length in LY294002 treated bones, but this
was not found statistically significant (Figure 3B).
Similar results were found when we calculated the length
of the zones reporting the measurements as percentage of
the entire growth plate, but in this case the decrease in
proliferative zone length was not found to be statistically
significant (Figure 3C). Since LY294002 had similar
effects on the proximal or distal growth plates (Figure 2C
and Figure 2D), zone measurements were performed on
the proximal growth plate only.
Treatment of tibiae with LY294002 results in reduced 
hypertrophic cell size
We next analyzed the effects of LY294002 on chondrocyte
morphology. While resting and proliferative cells did not
display obvious differences in cell size or shape under the
different conditions, cells in the hypertrophic zone
appeared markedly smaller upon PI3K inhibition (Figure
4A).
To examine whether the observed effects were specific for
the chosen developmental stage, we performed similar
experiments with tibiae from E18.5 mice. Tibiae cultured
for 6 days in the presence of LY294002 demonstrated
decreased length of the growth plate and the hypertrophic
zone, similar to E15.5 tibiae. We also noticed decreased
size of hypertrophic cells in the presence of the PI3K
inhibitor (Figure 4B), demonstrating that the anabolic
role of the PI3K pathway is not specific to a certain devel-
opmental stage.
Decreased markers of chondrocyte differentiation and 
increased apoptosis in LY294002 treated growth plates
We next examined molecular markers of chondrocyte dif-
ferentiation in E15.5 tibiae cultured for 6 days in the pres-
ence of LY294002 or DMSO, using
immunohistochemistry. The domain of collagen X stain-
ing was decreased upon PI3K inhibition (Figure 5A), in
agreement with the smaller hypertrophic zone observed
under these conditions. In addition, expression of cyclin-
dependent kinase inhibitor p57 (Kip2), a marker of post-
mitotic chondrocytes, was decreased in the LY294002
treated bones, providing further evidence for decreased
and delayed chondrocyte differentiation (Figure 5B).BMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
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PI3K inhibition results in reduced chondrocyte differentiation Figure 1
PI3K inhibition results in reduced chondrocyte differentiation. (A) Mesenchymal cells isolated from E11.5 mouse limb 
buds were cultured for 3 days and then treated with LY294002 or DMSO as vehicle control. They were stained after 6, 9 and 
12 days, respectively for different chondrocyte differentiation markers: Alcian blue for glycosaminoglycans, Alkaline phos-
phatase activity and Alizarin red for the calcium content. The intensity of these markers is reduced in the LY294002 treated 
cultures. (B) After 9 and 12 days respectively the Alcian blue content of the micromasses was spectrophotometrically meas-
ured at 620 nm, after extraction with 6 M Guanidine hydrochloride. We noticed decreased absorbance levels for the 
LY294002 treated cultures. (C) Measurements of Hoechst fluorescence intensity (excitation/emission: 350/450 nm) showed no 
significant difference in the DNA content between the LY294002 and DMSO treated micromass cultures. (D, E) RNA was iso-
lated from the micromass cultures after 6 and 9 days of culture and real time analysis was performed. The relative transcript 
levels for col2a1 and col10a1 were decreased in the LY294002 treated micromasses compared to the vehicle control.
0.5cm
Alcian blue          Alkaline phosphatase Alizarin red S             
Day 6 Day 9 Day 12 Day 12 Day 9 Day 6 Day 9 Day 12
DMSO
LY294002
A
Day6 Day9 Day12
0
10000
20000
30000
40000
0.0
0.1
0.2
0.3
0.4
0.5
Day6                      Day9
Col2a1
d6d d6l d9d d9l
0.0
0.5
1.0
1.5
2.0
2.5 *
B
Col10a1
d6d d6l d9d d9l
0.0
0.5
1.0
1.5 *
*
Day6 Day 9
*
Col2a1 Col10a1
p<0.05; n=3 *
E
A
l
c
i
a
n
b
l
u
e
 
q
u
a
n
t
i
f
i
c
a
t
i
o
n
(
a
b
s
o
r
b
a
n
c
e
)
 
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
/
G
A
P
D
H
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
/
G
A
P
D
H
Day6 Day 9
p<0.05; n=3 *
Day6 Day 9
H
o
e
c
h
s
t
 
s
t
a
i
n
 
F
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
C
p>0.05; n=4
D
DMSO
LY294002BMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
Page 5 of 15
(page number not for citation purposes)
Decreased growth of the LY294002 treated tibiae Figure 2
Decreased growth of the LY294002 treated tibiae. (A) E 15.5 mouse tibiae, cultured for 6 days in the presence of 
LY294002 or DMSO, were analyzed by immunohistochemistry, at the end of the time course. Phosphorylation of Akt at 
Ser473 was found to be reduced under PI3K inhibition with LY294002 (10 μM). Black arrows show cells expressing phosphor-
ylated Akt. (B) The difference between the length of the tibiae in the beginning and at the end of the time course represents 
the bone growth and it was found to be significantly reduced in bones treated with LY294002 (45% reduction) or PI3-K α 
inhibitor IV (500 nM) (35% reduction) compared to DMSO. (C) At the end of culture period the tibiae were also stained with 
Alcian blue/Alizarin red. We notice decreased length of both proximal (gp1) and distal (gp2) growth plates of tibiae treated 
with LY294002 or PI3-K α inhibitor IV. (D) Measurements of the growth plates and mineralized area (min) length confirmed 
the reduction of these under PI3K inhibition with LY294002. (E) When the gp1, gp2 and min were expressed as ratio of the 
entire bone length there is an increased ratio of the mineralized area in the LY294002 treated tibiae.
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Reduced length of the proliferative and hypertrophic zones under PI3K inhibition Figure 3
Reduced length of the proliferative and hypertrophic zones under PI3K inhibition. (A) E15.5 tibiae treated for 6 
days with LY294002 or DMSO were fixed, paraffin embedded and sectioned. Hematoxylin & eosin (H&E) staining shows 
decreased length of hypertrophic (HZ) and proliferative zones (PZ) and increased resting zone (RZ) length in the LY294002 
treated bones. (B) Measurements of three zones of the growth plate confirmed the reduction in length for the HZ and PZ in 
the LY294002 treated tibiae, but the RZ length zone was not found to be significantly increased. (C) The HZ length expressed 
as ratio from the entire growth plate length was found to be significantly decreases and the RZ significantly increased in the 
case of LY294002 treatment. The PZ ratio was found to be similar between the treatments.BMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
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PI3K inhibition affects chondrocyte morphology Figure 4
PI3K inhibition affects chondrocyte morphology. (A) E15.5 tibiae, cultured for 6 days in the presence of LY294002 or 
DMSO were stained with Safranin O for proteoglycan content. The chondrocyte morphology was analyzed by comparing the 
chondrocyte size in the three zones of the growth plate. We noticed a reduction of hypertrophic cell size in the case of hyper-
trophic chondrocytes. (B) E18.5 tibiae treated with LY294002 for 6 days showed the same reduction in hypertrophic zone 
length and cell size as the E15.5 treated tibiae.BMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
Page 8 of 15
(page number not for citation purposes)
Decreased markers of chondrocyte differentiation and increased apoptosis in the LY294002 treated tibiae Figure 5
Decreased markers of chondrocyte differentiation and increased apoptosis in the LY294002 treated tibiae. (A) 
E15.5 tibia organ cultures were analyzed by immunohistochemistry for collagen X expression. The hypertrophic cell area 
(marked by dashed blue circles), which showed positive collagen X stain, was smaller in the LY294002 treated bones. (B) Tibiae 
were also analyzed by immunohistochemistry for cyclin-dependent kinase inhibitor 1C (p57), a marker of cell cycle arrest in 
G1 and chondrocyte differentiation. There was a narrower area of p57 positive cells (showed by brackets) in the LY294002 
treated bones. (C) E 15.5 tibiae treated for 6 days with LY294002 shoed an increased number of apoptotic cells in the hyper-
trophic and mineralized areas (black arrows) as shown by colorimetric TUNEL assay.BMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
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We next examined the effects of PI3K inhibition on
chondrocyte proliferation and apoptosis. BrdU (Bromo-
deoxyuridine) labeling revealed no significant difference
in the percentage of replicating cells within the prolifera-
tive zone of the growth plate (data not shown). Treatment
of E15.5 tibiae with LY294002 or DMSO for 6 days results
in increased number of cells showing positive TUNEL
stain in the hypertrophic zone of LY294002 treated bones
(Figure 5C).
IGF1-induced bone growth partially requires PI3K activity
We next attempted to identify extracellular signals that
control bone growth through the PI3K pathway. IGF1 is a
known anabolic factor for endochondral bones [12] and
has been shown to activate PI3K signaling [22,24]. Tibiae
isolated from E15.5 mice were cultured in the presence of
IGF1 (50 ng/ml of medium), LY294002, control (0.1%
Bovine serum albumine (BSA) in PBS) or
IGF1+LY294002. IGF1 treatment caused a significant
increase in bone growth (around 70%) (Figure 6A). As
before, LY294002 treatment resulted in more than 45%
reduction in growth. However, IGF1 stimulated bone
growth to a similar degree in LY294002 treated bones
(Figure 6B), with the ratio between the bone growth in the
IGF1 treatment and control (1.73) being lower that the
ratio between the LY294002+IGF1 treatment and
LY294002 (2.67). There is no significant difference
between the control and LY294002+IGF1 treatment. This
suggests that in addition to PI3K, another pathway is
required for IGF1-induced bone growth. Histological
investigation demonstrated that IGF1 induced enlarge-
ment of the hypertrophic zone in the absence and pres-
ence of LY294002, as shown by increased hypertrophic
zone length in IGF1 treatment compared to control and in
LY294002+IGF1 treatment compared to LY294002 alone
(Figure 6C).
C-type natriuretic peptide-induced bone growth requires 
PI3K activity
We next turned our attention to CNP, another potent
stimulator of bone growth [33]. Tibiae were isolated from
E15.5 mice and treated with control (0.1% HCl-BSA in
PBS), CNP (10-6 M), LY294002 or CNP+LY294002. CNP
strongly stimulated bone growth in the absence of
LY294002. Upon PI3K inhibition, CNP-induced bone
growth is blocked (Figure 7A), with no significant differ-
ence between the LY294002 and LY294002+CNP treat-
ments. Similarly to IGF1, CNP induces an enlargement of
the hypertrophic zone but in this situation it seems to be
dependent on PI3K activity, as shown by reduction of the
hypertrophic zone length in the CNP+LY294002 treat-
ment almost to the level of the LY294002 treatment (Fig-
ure 7B).
Discussion
The PI3K pathway has been shown to affect numerous cel-
lular processes in a tissue-specific fashion; for example, it
is required for survival in different cell types such as cardi-
omyocytes [34], cellular differentiation in the case of oste-
oclasts and keratinocytes [35,36], and proliferation and
differentiation of osteoblasts [35]. It also stimulates differ-
entiation of CD4+ T-cells [37] and development and pro-
liferation of B cells [38,39]. We hypothesized that the
PI3K pathway has similar effects in the growth plate, pro-
moting endochondral bone growth by increasing prolifer-
ation and differentiation of chondrocytes and by
suppressing apoptosis.
We found that inhibition of PI3K with LY294002 results
in decreased differentiation, in both primary chondro-
cytes (micromass cultures) and organ cultures. Markers of
both early chondrocyte differentiation such as collagen II
and glycosaminoglycans and of late hypertrophic differ-
entiation such as collagen X, p57, Alkaline phosphatase
activity and calcium content (Alizarin red S stain) were
decreased upon PI3K inhibition. These data suggest that
the PI3K pathway is required for normal chondrocyte dif-
ferentiation. In the organ culture system, we have shown
that the PI3K pathway is required for maximal bone
growth, since by inhibiting the pathway we obtained 55%
reduction in bone growth, due to a proportionate shorten-
ing of both growth plates.
The major phenotype of the LY294002 treated tibiae is
represented by a 45% reduction in the length of the hyper-
trophic zone, providing further evidence that the PI3K
pathway is required for hypertrophic differentiation. The
observed reduction in the area staining for collagen X and
p57 in LY294002 treated tibiae is in agreement with
reduced hypertrophy. In addition we have seen a 20%
reduction of the length of the proliferative area of the
growth plate, in LY294002 treated tibiae. In the organ cul-
ture system it seems that the onset of proliferation is
delayed, since the resting zone represents a higher per-
centage of the growth plate in the LY294002 treated bones
compared to control. The ratio of BrdU labeled cells
within the proliferative zone of the growth plate does not
appear to be different between LY294002 and control cul-
tures, suggesting that PI3K inhibition results in delayed
cell cycle entry, but does not affect the rate of cell cycle
progression once cells have entered to proliferative zone.
Our data also show increased apoptosis in organ cultures
treated with LY294002. Apoptosis was only detected in
the hypertrophic and mineralized zones, suggesting that
the PI3K pathway is required for hypertrophic chondro-
cyte survival.
PI3K signaling transduces signals from many growth fac-
tors and other extracellular cues, but it is not knownBMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
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IGF1-induced bone growth partially requires PI3K activity Figure 6
IGF1-induced bone growth partially requires PI3K activity. (A)Tibiae isolated from E15.5 mice were cultured for 6 
days in the presence of IGF1 or 0.1% BSA in PBS, as control. IGF1 induced significant increase in bone growth. (B) Measure-
ments of bone growth after 6 days of treatment with IGF1, control, LY294002 or IGF1 + LY294002 showed increased bone 
growth in the IGF1 treatment, and similar bone growth between the control and the IGF1 + LY294002 treatment. (C) E 15.5 
tibiae treated for 6 days with the treatments mentioned above, were fixed, embedded, sectioned and stained with Safranin O. 
The length of hypertrophic zone was increased in the IGF1 treatment compared to control; decreased in the LY294002 treat-
ment as shown before and in the case of the IGF1 + LY294002 treatment similar to the control hypertrophic zone length.
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CNP-induced bone growth requires PI3K activity Figure 7
CNP-induced bone growth requires PI3K activity. (A) Tibiae isolated from E15.5 mice were cultured for 6 days in the 
presence of CNP, control (0.1% HCl-BSA in PBS), LY294002 or CNP + LY294002. Bone growth measurements showed 
increased bone growth in the CNP treatment, and no significant difference between the LY294002 and CNP+LY294002. (B) E 
15.5 tibiae treated for 6 days with the treatments mentioned above, were fixed, embedded, sectioned and stained with H&E. 
The length of hypertrophic zone was increased in the CNP treatment compared to control, decreased in the LY294002 treat-
ment and similar between LY294002 and CNP+LY294002
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which of them utilizes the pathway for anabolic effects on
endochondral bones. Potential candidates are IGFs, how-
ever, our data suggest, somewhat unexpectedly that IGF1
stimulates organ culture growth in the presence of
LY294002 to a similar degree as in control cultures. IGF1
treatment causes an increase in the length of hypertrophic
zone [11], and this increase is not completely blocked by
the PI3K inhibitor. This suggests that the PI3K pathway is
not the only and potentially not the major pathway
required for IGF1-induced bone growth and -hyper-
trophic differentiation in our organ culture system.
One potential problem that could partially explain the
lack of growth reduction in the IGF1 + LY294002 treat-
ment is that IGF1 possibly increased Akt phosphorylation
to a level that is no longer completely inhibited by 10 μM
LY294002. The mechanisms for IGF1 and CNP regulation
of the PI3K pathway in growth plate chondrocytes are not
the focus of this manuscript, but we plan to investigate the
implications of these two growth factors in more depth in
future studies. It will be important to see the levels of
phosphorylated Akt in all treatment combinations, by
performing immunohistochemistry and Western blotting
with protein isolated directly from the tibiae treated with
all treatment combinations (control, IGF1, LY294002 and
LY294002 + IGF1 or control, CNP, LY294002, and CNP
+LY294002). In addition, future measurements of growth
plate zones under all conditions might provide an expla-
nation for the sustained anabolic effects of IGF1even in
the presence of LY294002. Our results have shown that
the PI3K pathway is mostly involved in hypertrophic
chondrocyte differentiation, and also that the two ligands
IGF1 and CNP increase the length of hypertrophic zone
(Figures 6C and 7B). There were no obvious effects on the
other zones, but performing growth plate zone measure-
ments and molecular analyses (e.g. BrdU labeling) might
bring additional information in the future.
It will also be of interest to determine which other path-
ways mediate anabolic activities of IGFs in cartilage; the
other major signaling pathway implicated in IGF signal-
ing in other cells, the MEK-ERK (mitogen-activated pro-
tein kinase kinase/extracellular regulated kinase) cascade,
has been shown to suppress endochondral bone growth
[33,40-42] and is therefore an unlikely candidate for this
role.
Surprisingly, C-type natriuretic peptide (CNP), which is
not a known PI3K activator, was found to partially require
PI3K activity to stimulate bone growth. The CNP-induced
growth of cultured tibiae was blocked by the PI3K inhibi-
tor. One interesting finding was that the effect of CNP on
hypertrophy – a significant increase in the hypertrophic
zone length [13] – was inhibited by LY294002. These data
identify CNP as one signal requiring PI3K activity in carti-
lage, but there are other potential candidates for regula-
tion of the PI3K pathway in endochondral bone growth,
such as PTHrP (Parathyroid hormone-related protein)
and integrin ligands. Studies are under way in our labora-
tory to identify physiological activators of PI3K signaling
in cartilage.
The molecular mechanisms mediating the effects of PI3K
signaling in endochondral bone growth remain to be
identified. We show that Akt proteins are phosphorylated
under control conditions, and that this activation is
reduced under PI3K inhibition, resulting in reduced bone
growth, in agreement with reduced growth in Akt1-defi-
cient mice as well as mice deficient in multiple Akt
genes[43,44]. The PI3K/Akt pathway was shown to be
involved in Runx2 (runt related transcription factor 2) -
dependent osteoblast and chondrocyte differentiation in
2 cell lines, MC3T3-E1 and ATCDC5, respectively [45].
Therefore it represents a candidate for the PI3K involve-
ment in chondrocyte hypertrophy. Further investigations
of the PI3K/Akt mechanisms of chondrocyte differentia-
tion are necessary in order to find the direct targets of this
signaling pathway.
Conclusion
We have shown that PI3K is required for normal growth
plate chondrocyte differentiation and survival in vitro,
and therefore for endochondral bone growth. Future stud-
ies are required to further analyze the mechanisms by
which PI3K exerts these effects, investigating both the
molecules downstream of PI3K and the upstream activa-
tors of the pathway, and the mechanisms used by these
molecules in order to function within the PI3K/Akt path-
way.
Methods
Materials
Timed pregnant CD1 mice were purchased from Charles
River Laboratories. Cell culture and organ culture medium
components and general chemicals were purchased from
Sigma and Invitrogen. LY294002, PI3-K α inhibitor IV,
and the TdT-FragEL™ DNA Fragmentation Detection Kit
were purchased from Calbiochem, Antibodies for immu-
nohistochemistry were purchased from Sigma (mono-
clonal anti-collagen type X-C7974), Cell Signaling
Technology® (P-Akt (Ser 473) #4051; Akt #9272), Santa
Cruz Biotechnology® (Kip2 p57 (H-91)). Hoechst 33342
nuclear acid stain was purchased from MolecularProbes;
Pronase E, used for antigen retrieval in immunohisto-
chemistry, from Sigma (#P5147) and AEC substrate-chro-
mogen was purchased from Dako.
Micromass culture
Mouse embryos were dissected at E11.5 and mesenchy-
mal cells were isolated from limb buds by digestion for 90BMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
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minutes in dispase as described [46]. Cells were resus-
pended in medium containing 60% F12, 10% FBS, 0.25%
L-glutamine and 0.25% Penicillin-Streptomycin and
plated at high density (2.5 × 107 cells/ml) in 10 μl drop-
lets, to stimulate high density cellular contacts. The cells
were cultured for up to 12 days, and the medium was sup-
plemented with 2 μl beta-glycerophosphate (final concen-
tration 1 mM) and 20 μl ascorbic acid (final concentration
0.25 mM) for each ml of medium. Medium was changed
daily [46]. Cells were differentiated in micromass culture
for 3 days to allow chondrogenesis to occur before addi-
tion of LY294002 (10 μM) or DMSO and staining with
Alcian blue or Alizarin red S and for alkaline phosphatase
activity, as described [46-48]. Alcian blue-stained micro-
mass cultures were incubated with 500 μl of 6 M Guani-
dine hydrochloride over night to extract the stain, as
described [48]. The absorbance of the Alcian blue solution
was measured at 620 nm.
Measurement of DNA content in micromass cultures using 
Hoechst staining
The UV-excitable DNA stain Hoechst 33342 at final con-
centration of 5 μg/ml was used to quantify DNA content
in the micromass cultures. Micromass cultures from the
same trials used in the Alcian blue, Alizarin red and alka-
line phosphatase stains, plated in parallel wells, were used
for this experiment. Culture times, treatments and fixation
procedures were all carried out in the same conditions as
for the above mentioned stains. Cells were then incubated
with Hoechst DNA dye for 15 minutes, washed with PBS
and trypsinized 2 × 10 minutes at 37°C. The cells were
then centrifuged at 1000 rpm for 2 minutes and re-sus-
pended in culture medium. Re-suspended cells were used
to measure the DNA content in these cultures using a fluo-
rimeter (Model RF-M2004, Photon Technology Interna-
tional, London, ON) with excitation at 350 nm and
emission at 450 nm. Data from 3 different trials was ana-
lyzed using Felix32 Software.
RNA isolation and real-time PCR
RNA was isolated from micromass cultures as previously
described [49]. Taqman real-time PCR was performed to
quantitatively asses RNA samples [46,48,49] with primers
and probe sets from Applied Biosystems; data were nor-
malized to Gapdh (Glyceraldehyde 3-phosphate dehydro-
genase) mRNA levels and represent averages and SD from
direct comparison of LY294002 and DMSO treatments
from at least 3 different trials.
Organ culture
Tibiae were isolated from E15.5 mice and cultured for 6
days in medium containing alpha MEM, ascorbic acid,
beta-glycerophosphate, bovine serum albumine,
glutamine and Penicillin-Streptomycin, as described [13].
After dissection, the bones were incubated in this medium
over night and then treated with LY294002 (10 μM), PI3-
K α inhibitor IV (500 nM) or DMSO. In the case of IGF1
treatments the tibiae were cultured in the presence of con-
trol (0.1% Bovine serum albumine (BSA) in PBS with
DMSO), IGF1- 50 ng/ml- (with DMSO), LY294002 (with
0.1% BSA) or IGF1+LY294002. The control for CNP was
0.1% HCl-BSA in PBS and the CNP concentration used,
10-6 M. The treatments were organized similar to IGF1.
Media and supplements were changed every two days. The
bone length was measured at the beginning (before any
treatment) and end of the time course. After 6 days of
treatment, organs were fixed and paraffin embedded. 5
μm sections were stained with Hematoxylin and Eosin
(H&E), Safranin O/Fast green and Alcian blue and then
analyzed using a Leica DMRA2 microscope. Whole tibiae
were also stained with Alcian blue/Alizarin red S.
Histology and immunohistochemistry
Histology and immunohistochemistry procedures were
performed as described [50] with minor modifications.
Sections were incubated in 3% H2O2 for 15 min at room
temperature, followed by boiling for 2 min and incuba-
tion for 30 min at 97°C in 10 mM sodium citrate (pH 6.0)
or pronase E treatment (1 mg/ml of PBS) for 10 min in the
case of collagen X. They were then blocked with 5% goat
serum. Sections were incubated with primary antibodies
over night at 4°C. The UltraVision LP Large Volume
Detection System AP Polymer was then used to recognize
the primary antibodies according to manufacturer's
instructions. After washing, the HRP (horseradish peroxi-
dase) conjugated polymer complex was visualized by
incubation for 2–10 min with AEC (3-amino-9-ethylcar-
bazole) substrate-chromogen and then sections were
washed and mounted. All images were taken at room tem-
perature with a Retiga EX camera connected to a Leica
DMRA2 microscope. Primary image analyses were per-
formed using Openlab 4.0.4 software.
TUNEL assay
The bones were cultured for 6 days in the presence of
LY294002 or DMSO, fixed in 4% Paraformaldehyde and
paraffin embedded. 5 μm sections were used for the
TUNEL assay using the Calbiochem® DNA Fragmentation
Detection Kit according to manufacturer's instructions.
Statistical analysis
All data were collected from at least 3 independent trials,
which were run in triplicate or quadruplicate. Data were
expressed as mean ± SD, and * p values under 0.05 were
considered significant (*). Statistical significance was
determined by one-way ANOVA (for Figure 2B) and two-
way ANOVA (for the rest of the graphs), with Bonferroni
post-test using GraphPad Prism 3.00 for Windows.BMC Developmental Biology 2008, 8:40 http://www.biomedcentral.com/1471-213X/8/40
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